Combined archive search across FBI Vault, SPLC, PHMPT, ACIP, NIH grants, the Federal Writers' Project, and other collections we've ingested.
JOHN P MOORE · WEILL MEDICAL COLL OF CORNELL UNIV · 2024 · $500,527 — Project Summary/Abstract Many potent and effective broadly neutralizing antibodies (bNAbs) directed to the HIV-1 envelope glycoprotein (Env) trimer have been studied mechanistically and structurally. Combined, their epitopes now cover most of the external surface of Env. Passive immunization with bN…
JAY PONDER · WASHINGTON UNIVERSITY · 2024 · $298,071 — PROJECT SUMMARY/ABSTRACT Nucleic acids (NAs) are the major information carrying molecules of life. The ability to use computation to model the structure, dynamic and interactions of DNA and RNA is a key adjunct to experimental study of these biomolecules. For example, pseudouridine-containing mRNA v…
Hannah Frizzell · ORLANCE, INC. · 2024 · $200,000 — PROJECT SUMMARY Orlance has developed a next-generation Gene Gun (MACH-1 GG) that efficiently delivers DNA and RNA into epidermal cells, leading to robust immune responses. Sequencing of tumors from individual patients has led to the identification of personalized neoantigens that could be targeted …
SCOTT W WONG · OREGON HEALTH & SCIENCE UNIVERSITY · 2024 · $1,212,634 — SUMMARY The overall goals of this U01 application are two-fold. First, to investigate two potential KSHV targets, one structural and one non-structural, to determine if these two targets are capable of protecting vaccinated animals from infection. And, the second, to compare two vaccine strategies t…
LLOYD M SMITH · UNIVERSITY OF WISCONSIN-MADISON · 2024 · $532,733 — Project Summary/Abstract The complexity of the HIV-1 transcriptome has been progressively revealed throughout recent decades using increasingly advanced RNA sequencing technologies. However, knowledge of the RNA primary sequence alone has not been sufficient to determine the importance or function o…
DANIEL G ANDERSON · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · 2024 · $726,005 — Many HIV vaccine candidates have failed clinical trials, as they were unable to elicit a potent and durable response to HIV viral challenge. Broadly neutralizing antibodies (bnAbs) have been identified in a number of HIV+ individuals with well-controlled viral levels, and these bnAbs target epitopes…
Leonidas Stamatatos · FRED HUTCHINSON CANCER CENTER · 2024 · $1,393,751 — ABSTRACT OVERALL The main goal of our IPCAVD Program grant is to evaluate in humans self-amplifying mRNA (saRNA) vaccines that express two HIV-1 Env-derived protein immunogens that activate and initiate the maturation of VRC01-class B cell receptors (BCRs). The first immunogen, 426c.Mod.Core, was sp…
JOHN M MARIS · CHILDREN'S HOSP OF PHILADELPHIA · 2024 · $178,000 — PROJECT SUMMARY: U01 CA217959 Supplement Application This application is being submitted in response to the Notice of Special Interest (NOSI) identified as NOT-CA- 24-029. The parent Multiple Principal Investigator (MPI) Project proposal for the Pediatric Immunotherapy Network is focused on high-ris…
Erol Fikrig · L2 DIAGNOSTICS, LLC · 2024 · $299,969 — PROJECT SUMMARY Chikungunya is an arboviral disease transmitted to humans by infected mosquitoes, primarily the Aedes aegypti and Aedes albopictus species. The virus responsible for the disease is the chikungunya virus (CHIKV), a member of the Togaviridae family. First identified in Tanzania in 195…
Barton F. Haynes · DUKE UNIVERSITY · 2024 · $3,192,992 — Supplement request to DAIDS to Manufacture an mRNA/LNP encoding an HIV envelope designed to bind and stimulate multiple V2 Apex broadly neutralizing antibody B cell lineages Barton Haynes, CHAVD PI Thomas Denny, Investigator, manufacture team This request is to produce GMP an mRNA immunogen that enc…
Edward P Browne · UNIV OF NORTH CAROLINA CHAPEL HILL · 2024 · $415,427 — Project summary: Antiretroviral therapy (ART) has been successful at treating HIV infection and allowing people with HIV (PWH) to lead relatively normal lives. Nevertheless, a cure for HIV has remained elusive, and interruption of ART results in rapid viral rebound. HIV persists during therapy by it…
Yan Tang · TUFTS UNIVERSITY MEDFORD · 2024 · $659,481 — Abstract Lymphangioleiomyomatosis (LAM) is a genetic disorder caused by bi-allelic inactivating mutations in tumor suppressor genes TSC1 or TSC2, leading to progressive lung destruction and eventually the requirement for lung transplantation. Rapalogs, the only FDA-approved treatments for LAM, induc…
Paul Stephen Keim · NORTHERN ARIZONA UNIVERSITY · 2024 · $1,416,075 — OVERALL Section Title: Early in vivo expressed antigens and their role in virulence, immune response, and vaccines for coccidioidomycosis. SUMMARY Coccidioidomycosis, also known as Valley Fever (VF), is an important fungal disease caused by two different Coccidioides species that results in regional…
James D. Bryers · UNIVERSITY OF WASHINGTON · 2024 · $540,184 — While Staphylococcus aureus (SA) commonly asymptomatically colonizes the skin and nose of healthy humans, severe disease can result from infection of the blood, bone, skin, and lungs, as well as sites of catheters and prosthetic devices. With currently approved therapy, about one-third of patients d…
Kristin Palmsten · HEALTHPARTNERS INSTITUTE · 2024 · $548,002 — The efficacy of coronavirus disease (COVID-19) vaccines available in the US is up to 95% against symptomatic COVID-19. However, pregnant and lactating individuals were excluded from initial clinical trials. COVID-19 vaccine trials are now underway in pregnant women in their second or third trimester…
Eleftherios Michailidis · EMORY UNIVERSITY · 2024 · $21,207 — Project Summary There are approximately a quarter of a billion people worldwide chronically infected with hepatitis B virus (HBV) who are at risk of developing liver cirrhosis and hepatocellular carcinoma. The loss of life due to HBV-related complications each year is about 820,000 people. At the sa…
Sharon Aviran · UNIVERSITY OF CALIFORNIA AT DAVIS · 2024 · $164,971 — Natural and synthetic RNAs play key roles in cellular function, biotechnology, and medicine. RNAs fold into intricate structures, which often drive their functions, thus determining RNA structure is fundamental to biology and biotechnology. Computational thermodynamics-based secondary structure mode…
Brian Lim Hoh · UNIVERSITY OF FLORIDA · 2024 · $75,099 — Diffuse Midline Glioma (DMG) is an inoperable pediatric brain tumor with no good treatment options. Our group has developed a novel treatment modality for this disease and others, using mRNA vaccines consisting of tumor derived antigens packed into a unique lipid nanoparticle (NP). They can provide …
FREDERICK R BLATTNER · SCARAB GENOMICS, LLC · 2024 · $842,151 — Abstract E. coli has played a vital role in the production of recombinant proteins and plasmid DNA (pDNA) for therapeutic use since the advent of the biopharmaceutical industry. E. coli remains the workhorse in the production of heterologous proteins and pDNA because of its short doubling time, its …
Somes Kumar Das · AVERY BIO CORPORATION · 2024 · $295,923 — The long-term objective of this research program is to greatly increase the availability of large DNA constructs for biomedical researchers, by providing a new, highly automated, and low-cost way of making long synthetic DNA molecules. Gene-length DNA is routinely used by genetic engineers to delive…